Lantheus Holdings, Inc

LNTH trades at a 24.5 P/E while sitting at its 52-week high—an aggressive valuation paired with extended technicals, as the RSI approaches overbought territory at 60.5. The 10.44% short interest suggests meaningful skepticism remains among bears, but that position could catalyze a sharp squeeze if momentum accelerates. For a diagnostic company at peak price levels, the combination of elevated multiples and near-overbought momentum creates execution risk; any earnings disappointment or sector rotation could unwind gains quickly. The diagnostic imaging market's growth narrative may justify premium pricing, yet the setup feels stretched rather than compelling on a risk-reward basis.